Current clinical data demonstrates that roxadustat is superior to placebo and/or non-inferior to ESAs in correcting and/or maintaining hemoglobin (Hb) concentration at target levels among patients with non-dialysis dependent CKD (NDD-CKD) and incident and dialysis dependent CKD (DD-CKD). The gene discussed is GSTM1; the disease is chronic kidney disease.